JPWO2019147867A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019147867A5 JPWO2019147867A5 JP2020539709A JP2020539709A JPWO2019147867A5 JP WO2019147867 A5 JPWO2019147867 A5 JP WO2019147867A5 JP 2020539709 A JP2020539709 A JP 2020539709A JP 2020539709 A JP2020539709 A JP 2020539709A JP WO2019147867 A5 JPWO2019147867 A5 JP WO2019147867A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding fragment
- group
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023030129A JP2023060018A (ja) | 2018-01-26 | 2023-02-28 | インフルエンザヘマグルチニンに対するヒト抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622480P | 2018-01-26 | 2018-01-26 | |
| US62/622,480 | 2018-01-26 | ||
| PCT/US2019/015029 WO2019147867A1 (en) | 2018-01-26 | 2019-01-24 | Human antibodies to influenza hemagglutinin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030129A Division JP2023060018A (ja) | 2018-01-26 | 2023-02-28 | インフルエンザヘマグルチニンに対するヒト抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511043A JP2021511043A (ja) | 2021-05-06 |
| JPWO2019147867A5 true JPWO2019147867A5 (he) | 2022-02-07 |
| JP7372925B2 JP7372925B2 (ja) | 2023-11-01 |
Family
ID=66286952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539709A Active JP7372925B2 (ja) | 2018-01-26 | 2019-01-24 | インフルエンザヘマグルチニンに対するヒト抗体 |
| JP2023030129A Withdrawn JP2023060018A (ja) | 2018-01-26 | 2023-02-28 | インフルエンザヘマグルチニンに対するヒト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030129A Withdrawn JP2023060018A (ja) | 2018-01-26 | 2023-02-28 | インフルエンザヘマグルチニンに対するヒト抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11780907B2 (he) |
| EP (1) | EP3743442A1 (he) |
| JP (2) | JP7372925B2 (he) |
| KR (1) | KR20200115517A (he) |
| CN (1) | CN111670195A (he) |
| AU (1) | AU2019212480A1 (he) |
| BR (1) | BR112020014849A2 (he) |
| CA (1) | CA3088194A1 (he) |
| CL (1) | CL2020001884A1 (he) |
| CO (1) | CO2020009043A2 (he) |
| EA (1) | EA202091563A1 (he) |
| IL (1) | IL275884A (he) |
| MA (1) | MA51681A (he) |
| MX (1) | MX2020007772A (he) |
| PH (1) | PH12020551051A1 (he) |
| SG (1) | SG11202006379UA (he) |
| WO (1) | WO2019147867A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023519930A (ja) * | 2020-04-01 | 2023-05-15 | ユニバーシティ オブ ロチェスター | インフルエンザｈ３ｎ２ウイルスのヘマグルチニン（ｈａ）およびノイラミニダーゼ（ｎａ）に対するモノクローナル抗体 |
| IL302938A (he) * | 2020-11-23 | 2023-07-01 | Vir Biotechnology Inc | נוגדנים נגד נגיפי שפעת a |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CA2608656A1 (en) * | 2005-05-16 | 2006-11-23 | Morphotek, Inc. | Regulated vectors for selection of cells exhibiting desired phenotypes |
| EP2374818B1 (en) | 2006-06-02 | 2012-12-19 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| AU2007293662B2 (en) | 2006-09-07 | 2012-10-04 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
| EP1947423A1 (en) | 2007-01-16 | 2008-07-23 | Sony Deutschland Gmbh | Distance, orientation and velocity sensitive controller |
| KR101421460B1 (ko) | 2007-05-11 | 2014-07-30 | 테마섹 라이프 사이언스 래보러토리 리미티드 | Ｈ５ 조류 인플루엔자 진단 및 감시를 위해 유용한 ｈ５ 서브타입-특이적 결합 단백질 |
| AU2008297586B2 (en) | 2007-09-13 | 2013-06-20 | National Institute Of Health Research And Development (Nihrd)- Ministry Of Health Of The Republic Of Indonesia | Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof |
| AU2008297594B2 (en) | 2007-09-13 | 2013-06-20 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
| RU2010127156A (ru) | 2007-12-06 | 2012-01-20 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Антитела против вируса гриппа и их применение |
| AU2008349862B2 (en) | 2008-02-05 | 2014-02-06 | Temasek Life Sciences Laboratory Limited | Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses |
| EP2274334A2 (en) | 2008-03-28 | 2011-01-19 | Sea Lane Biotechnologies,llc. | Neutralizing molecules to viral antigens |
| KR101732056B1 (ko) | 2008-07-25 | 2017-05-02 | 인스티튜트 포 리서치 인 바이오메드슨 | 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도 |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EP2328928A2 (en) | 2008-08-25 | 2011-06-08 | Dana-Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
| WO2010074656A1 (en) | 2008-12-24 | 2010-07-01 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof |
| WO2010073647A1 (ja) * | 2008-12-25 | 2010-07-01 | 国立大学法人大阪大学 | 抗ヒトインフルエンザウイルス・ヒト型抗体 |
| CN102448986B (zh) | 2009-05-11 | 2015-11-25 | 克鲁塞尔荷兰公司 | 能中和流感病毒h3n2的人结合分子及其应用 |
| EP2430047B1 (en) | 2009-05-13 | 2018-03-28 | i2 Pharmaceuticals, Inc. | Neutralizing molecules to influenza viruses |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| HUE029785T2 (en) | 2010-02-08 | 2017-04-28 | Regeneron Pharma | Common mouse light chain |
| CN102791734B (zh) | 2010-03-08 | 2014-10-15 | 赛特瑞恩股份有限公司 | 源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体 |
| AU2011268072C1 (en) | 2010-06-17 | 2017-10-19 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| WO2012045001A2 (en) | 2010-09-30 | 2012-04-05 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
| CN103906763B (zh) | 2011-07-14 | 2016-10-12 | 克鲁塞尔荷兰公司 | 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子 |
| ITRM20110606A1 (it) | 2011-11-16 | 2013-05-17 | Ist Superiore Sanita | Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza. |
| KR20140112495A (ko) | 2011-12-02 | 2014-09-23 | 에임 쎄라퓨틱스 비.브이. | 인플루엔자 a 바이러스 특이적 항체 |
| DK2793945T3 (en) | 2011-12-05 | 2018-09-03 | Trellis Bioscience Llc | USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION |
| MY170407A (en) | 2012-03-08 | 2019-07-27 | Crucell Holland Bv | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| EP2919813B1 (en) | 2012-11-13 | 2018-10-24 | F.Hoffmann-La Roche Ag | Anti-hemagglutinin antibodies and methods of use |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| RU2683498C2 (ru) | 2013-10-02 | 2019-03-28 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа а и пути их применения |
| CN106795216B (zh) * | 2014-02-04 | 2021-04-20 | 抗非特公司 | 可用于被动流感免疫的抗体及其组合物、组合和使用方法 |
| CA2942820A1 (en) | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Anti-influenza b virus hemagglutinin antibodies and methods of use |
| CN104031118B (zh) | 2014-06-19 | 2016-04-13 | 天津大学 | 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法 |
| TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10435462B2 (en) | 2015-03-31 | 2019-10-08 | Viro Dynamics Corporation | Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza |
| JP6960856B2 (ja) * | 2015-04-08 | 2021-11-05 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
| SI3303384T1 (sl) | 2015-06-01 | 2021-11-30 | Medimmune Llc | Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2020221450A1 (en) | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies and methods for treatment of influenza a infection |
-
2019
- 2019-01-24 EA EA202091563A patent/EA202091563A1/ru unknown
- 2019-01-24 SG SG11202006379UA patent/SG11202006379UA/en unknown
- 2019-01-24 US US16/964,579 patent/US11780907B2/en active Active
- 2019-01-24 CN CN201980009873.XA patent/CN111670195A/zh active Pending
- 2019-01-24 JP JP2020539709A patent/JP7372925B2/ja active Active
- 2019-01-24 EP EP19719656.1A patent/EP3743442A1/en active Pending
- 2019-01-24 AU AU2019212480A patent/AU2019212480A1/en active Pending
- 2019-01-24 BR BR112020014849-0A patent/BR112020014849A2/pt unknown
- 2019-01-24 WO PCT/US2019/015029 patent/WO2019147867A1/en unknown
- 2019-01-24 MA MA051681A patent/MA51681A/fr unknown
- 2019-01-24 CA CA3088194A patent/CA3088194A1/en active Pending
- 2019-01-24 KR KR1020207022064A patent/KR20200115517A/ko active Search and Examination
- 2019-01-24 MX MX2020007772A patent/MX2020007772A/es unknown
-
2020
- 2020-07-06 IL IL275884A patent/IL275884A/he unknown
- 2020-07-07 PH PH12020551051A patent/PH12020551051A1/en unknown
- 2020-07-17 CL CL2020001884A patent/CL2020001884A1/es unknown
- 2020-07-23 CO CONC2020/0009043A patent/CO2020009043A2/es unknown
-
2023
- 2023-02-28 JP JP2023030129A patent/JP2023060018A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503361A5 (he) | ||
| JP6711828B2 (ja) | インフルエンザ赤血球凝集素に対するヒト抗体 | |
| JP2018506966A5 (he) | ||
| US10532086B2 (en) | Methods and compositions for modulating the immune system with arginase I | |
| US8252906B2 (en) | Anti-herpes simplex virus antibodies and methods of use thereof | |
| ES2909720T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y un análogo de purina | |
| JP2019528050A (ja) | 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法 | |
| JP2010528601A5 (he) | ||
| JPWO2021183359A5 (he) | ||
| KR20150138236A (ko) | 향상된 치료 효능을 위해 비강내로 전달되는 중화 항체에 기반한 조성물 및 방법 | |
| US8012478B2 (en) | Use of anti-IL-20 antibody for treating stroke | |
| JP2018533937A (ja) | Ｂ型肝炎表面抗原に対する抗体及びその使用 | |
| JP2019534003A5 (he) | ||
| CA3185105A1 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| WO2010078518A1 (en) | Anti-herpes simplex virus antibodies and methods of use thereof | |
| JPWO2019147867A5 (he) | ||
| BR112020014849A2 (pt) | Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza | |
| US20210332112A1 (en) | Stabilized pertussis antibodies with extended half-life | |
| CA2729226C (en) | Pharmaceutical compositions of antibodies for diseases caused by viruses | |
| US7572449B2 (en) | Vaccine against Yersinia comprising one or two antibodies, one specific for Yersinia pestis F1-antigen and the other one for Yersinia pestis V-antigen | |
| US20240156935A1 (en) | Vaccine Compositions for Trypanosomatids | |
| AU2021258112A1 (en) | PAN-ELR+ CXC chemokine antibodies for the treatment of respiratory disease | |
| WO2016189491A1 (en) | Novel formulation | |
| US20240218056A1 (en) | Nucleocapsid-specific antibodies and methods for the treatment and prevention of sars-cov-2 infection therewith | |
| Bozorgmanesh et al. | A Review on Common Treatments for COVID-19 and Use of Tocilizumab (ACTEMRA) in Reducing Effects of the Disease |